Episode # 56 • 21 Apr 2026
Breast Cancer Precision Medicine: Biomarkers & Treatments
Here’s a practical guide on how biomarkers can guide treatment and cut costs for your breast cancer patients. In this episode of the BackTable Tumor Board Podcast, Dr. Lindsay Peterson and Dr. Jessica Trevino Jones review the role of precision medicine and biomarkers in early-stage and metastatic disease, specifically in breast cancer.
Timestamps
00:00 - Introduction
05:30 - Genomic Testing in the Metastatic Setting
11:47 - Liquid vs Tissue Biopsy
17:51 - Testing and Treatment for Triple Negative Metastatic Breast Cancer
21:20 - Precision Medicine and Patient Education
27:01 - Path CR and Residual Disease: Clinical Trials
37:01 - Neratinib in Triple Positive Breast Cancer and Brain Metastasis
39:55 - Genomic Tests: Oncotype and MammaPrint
43:45 - Importance of Clinical Trials and Wellness Support
Resources
You may also like
More about this episode
Dr. Peterson and Dr. Trevino Jones discuss the optimal timing for tumor genomic testing in ER-positive/HER2-negative and triple-negative metastatic breast cancer, and examine the decision-making process between liquid biopsy and tissue biopsy for biomarker analysis. The conversation also highlights how these technological advances can expand treatment options and help reduce financial toxicity for patients. Additionally, the doctors emphasize the importance of patient education about clinical trials, address common misconceptions, and discuss the integration of prevention, nutrition, exercise, and wellness support into comprehensive cancer care.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.